Zokinvy
NDC Package 73079-075-30
Package Information
Zokinvy is indicated in patients 12 months of age and older with a body surface area (BSA) of 0.39 m2 and above: To reduce the risk of mortality in Hutchinson-Gilford Progeria Syndrome (HGPS)For the treatment of processing-deficient Progeroid Laminopathies with either: Heterozygous LMNA mutation with progerin-like protein accumulationHomozygous or compound heterozygous ZMPSTE24 mutations Limitations of UseZOKINVY is not indicated for other Progeroid Syndromes or processing-proficient Progeroid Laminopathies. Marketed by Eiger Biopharmaceuticals, Inc., this product is identified by NDC 73079-075 and is authorized under FDA application NDA213969.
Identification & Billing
- RxCUI: 2467582 - lonafarnib 50 MG Oral Capsule
- RxCUI: 2467588 - Zokinvy 50 MG Oral Capsule
- RxCUI: 2467588 - lonafarnib 50 MG Oral Capsule [Zokinvy]
- RxCUI: 2467590 - lonafarnib 75 MG Oral Capsule
- RxCUI: 2467592 - Zokinvy 75 MG Oral Capsule
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 73079 - Eiger Biopharmaceuticals, Inc.
- 73079-075 - Zokinvy
- 73079-075-30 - 1 BOTTLE, PLASTIC in 1 CARTON / 30 CAPSULE in 1 BOTTLE, PLASTIC
- 73079-075 - Zokinvy
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 73079-075-30 identifies a specific commercial package of 1 bottle, plastic in 1 carton / 30 capsule in 1 bottle, plastic of Zokinvy, labeled by Eiger Biopharmaceuticals, Inc.. This product is billed for "EA" each discreet unit and contains an estimated amount of 1 billable units per package. This is formulated for use and contains as the active substance.
Is this product currently listed with the FDA?
This product code is currently listed as inactive or excluded from the primary directory. It was introduced to the market by Eiger Biopharmaceuticals, Inc. on November 20, 2020. The current certification is valid through December 31, 2025.
How is this Eiger Biopharmaceuticals, Inc. product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 73079007530. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. There are 1 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Product segment to maintain the 5-4-2 structure.